Non-motor symptom burden in patients with Parkinson's disease with impulse control disorders and compulsive behaviours: results from the COPPADIS cohort

Sci Rep. 2020 Oct 9;10(1):16893. doi: 10.1038/s41598-020-73756-z.

Abstract

The study was aimed at analysing the frequency of impulse control disorders (ICDs) and compulsive behaviours (CBs) in patients with Parkinson's disease (PD) and in control subjects (CS) as well as the relationship between ICDs/CBs and motor, nonmotor features and dopaminergic treatment in PD patients. Data came from COPPADIS-2015, an observational, descriptive, nationwide (Spain) study. We used the validated Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale (QUIP-RS) for ICD/CB screening. The association between demographic data and ICDs/CBs was analyzed in both groups. In PD, this relationship was evaluated using clinical features and treatment-related data. As result, 613 PD patients (mean age 62.47 ± 9.09 years, 59.87% men) and 179 CS (mean age 60.84 ± 8.33 years, 47.48% men) were included. ICDs and CBs were more frequent in PD (ICDs 12.7% vs. 1.6%, p < 0.001; CBs 7.18% vs. 1.67%, p = 0.01). PD patients had more frequent previous ICDs history, premorbid impulsive personality and antidepressant treatment (p < 0.05) compared with CS. In PD, patients with ICDs/CBs presented younger age at disease onset, more frequent history of previous ICDs and premorbid personality (p < 0.05), as well as higher comorbidity with nonmotor symptoms, including depression and poor quality of life. Treatment with dopamine agonists increased the risk of ICDs/CBs, being dose dependent (p < 0.05). As conclusions, ICDs and CBs were more frequent in patients with PD than in CS. More nonmotor symptoms were present in patients with PD who had ICDs/CBs compared with those without. Dopamine agonists have a prominent effect on ICDs/CBs, which could be influenced by dose.

Publication types

  • Observational Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antidepressive Agents
  • Cohort Studies
  • Comorbidity
  • Compulsive Behavior / drug therapy
  • Compulsive Behavior / metabolism
  • Compulsive Behavior / physiopathology*
  • Cross-Sectional Studies
  • Disruptive, Impulse Control, and Conduct Disorders / drug therapy
  • Disruptive, Impulse Control, and Conduct Disorders / metabolism
  • Disruptive, Impulse Control, and Conduct Disorders / physiopathology*
  • Dopamine / metabolism
  • Dopamine Agonists / therapeutic use
  • Female
  • Follow-Up Studies
  • Humans
  • Impulsive Behavior / drug effects
  • Impulsive Behavior / physiology*
  • Male
  • Middle Aged
  • Parkinson Disease / drug therapy
  • Parkinson Disease / metabolism
  • Parkinson Disease / physiopathology*
  • Quality of Life
  • Risk Factors
  • Spain
  • Surveys and Questionnaires

Substances

  • Antidepressive Agents
  • Dopamine Agonists
  • Dopamine